Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clio P Mavragani

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Plos One|February 28, 2015
Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patientsAristea Papageorgiou, Dimitrios C Ziogas, Clio P Mavragani, et al.
Journal of Clinical Medicine|September 10, 2021
+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren's Syndrome: Potential Clinical and Pathogenetic ImplicationsCharalampos Skarlis, Nikolaos Marketos, Adrianos Nezos, et al.
Arthritis and Rheumatism|December 1, 2007
Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanerceptClio P Mavragani, Timothy B Niewold, Niki M Moutsopoulos, et al.
Journal of Autoimmunity|July 18, 2015
Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesisAdrianos Nezos, Fotini Gravani, Anna Tassidou, et al.
Inflammatory Bowel Diseases|August 20, 2020
Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the MicrobiotaClio P Mavragani, Adrianos Nezos, Nikolas Dovrolis, et al.
Journal of Clinical Medicine|November 13, 2025
Type I Interferon-Related Gene Expression and Laboratory Abnormalities in Acute Infection Are Associated with Long COVID Symptom BurdenMary Emmanouil, Vasiliki E Georgakopoulou, Konstantinos Drougkas, et al.
Frontiers in Immunology|October 30, 2020
Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic SclerosisNikolaos I Vlachogiannis, Maria Pappa, Panagiotis A Ntouros, et al.
Journal of Autoimmunity|April 22, 2025
Evaluation of minor labial salivary gland focus score in Sjögren's disease using deep learning: a tool for more efficient diagnosis and future tissue biomarker discoveryKonstantinos N Panagiotopoulos, Nikos Tsiknakis, Dimitrios I Zaridis, et al.
Clinical Immunology (Orlando, Fla.)|March 5, 2018
Contribution of MTHFR gene variants in lupus related subclinical atherosclerosisMaira Giannelou, Andrianos Nezos, Sofia Fragkioudaki, et al.
Arthritis Research & Therapy|April 18, 2015
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associationsFotini Gravani, Ioanna Papadaki, Eleni Antypa, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Plos One|February 28, 2015
Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patientsAristea Papageorgiou, Dimitrios C Ziogas, Clio P Mavragani, et al.
Journal of Clinical Medicine|September 10, 2021
+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren's Syndrome: Potential Clinical and Pathogenetic ImplicationsCharalampos Skarlis, Nikolaos Marketos, Adrianos Nezos, et al.
Arthritis and Rheumatism|December 1, 2007
Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanerceptClio P Mavragani, Timothy B Niewold, Niki M Moutsopoulos, et al.
Journal of Autoimmunity|July 18, 2015
Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesisAdrianos Nezos, Fotini Gravani, Anna Tassidou, et al.
Inflammatory Bowel Diseases|August 20, 2020
Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the MicrobiotaClio P Mavragani, Adrianos Nezos, Nikolas Dovrolis, et al.
Journal of Clinical Medicine|November 13, 2025
Type I Interferon-Related Gene Expression and Laboratory Abnormalities in Acute Infection Are Associated with Long COVID Symptom BurdenMary Emmanouil, Vasiliki E Georgakopoulou, Konstantinos Drougkas, et al.
Frontiers in Immunology|October 30, 2020
Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic SclerosisNikolaos I Vlachogiannis, Maria Pappa, Panagiotis A Ntouros, et al.
Journal of Autoimmunity|April 22, 2025
Evaluation of minor labial salivary gland focus score in Sjögren's disease using deep learning: a tool for more efficient diagnosis and future tissue biomarker discoveryKonstantinos N Panagiotopoulos, Nikos Tsiknakis, Dimitrios I Zaridis, et al.
Clinical Immunology (Orlando, Fla.)|March 5, 2018
Contribution of MTHFR gene variants in lupus related subclinical atherosclerosisMaira Giannelou, Andrianos Nezos, Sofia Fragkioudaki, et al.
Arthritis Research & Therapy|April 18, 2015
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associationsFotini Gravani, Ioanna Papadaki, Eleni Antypa, et al.
Pageof 12